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Summary
Background: Proteasome inhibitors are widely used in the
treatment of multiple myeloma and as research tools. Addi-
tionally, diminished proteasome function may contribute to
neuronal dysfunction. In response to these inhibitors, cells
enhance the expression of proteasome subunits by the tran-
scription factor Nrf1. Here, we investigate the mechanisms
by which decreased proteasome function triggers production
of new proteasomes via Nrf1.
Results: Exposure of myeloma or neuronal cells to protea-
some inhibitors (bortezomib, epoxomicin, and MG132), but
not to proteotoxic or ER stress, caused a 2- to 4-fold increase
within 4 hr in mRNAs for all 26S subunits. In addition, p97 and
its cofactors (Npl4, Ufd1, and p47), PA200, and USP14 were
induced, but expression of immunoproteasome-specific sub-
units was suppressed. Nrf1 mediates this induction of protea-
somes and p97, but only upon exposure to low concentrations
of inhibitors that partially inhibit proteolysis. Surprisingly, high
concentrations of these inhibitors prevent this compensatory
response. Nrf1 is normally ER-bound, and its release requires
its deglycosylation and ubiquitination. Normally ubiquitinated
Nrf1 is rapidly degraded, but when partially inhibited, protea-
somes carry out limited proteolysis and release the processed
Nrf1 (lacking its N-terminal region) from the ER, which allows it
to enter the nucleus and promote gene expression.
Conclusions: When fully active, proteasomes degrade Nrf1,
but when partially inhibited, they perform limited proteolysis
that generates the active form of Nrf1. This elegantmechanism
allows cells to compensate for reduced proteasome function
by enhancing production of 26S subunits and p97.
Introduction
The ubiquitin-proteasome system (UPS) catalyzes the degra-
dation of most proteins in eukaryotic cells. In the UPS, sub-
strates are targeted for degradation by 26S proteasomes by
attachment of a chain of ubiquitins (Ubs). Most ubiquitinated
proteins are then rapidly degraded by the 26S proteasome.
This ATP-dependent proteolytic complex consists of the 20S
proteolytic particle capped by one or two 19S regulatory par-
ticles, which bind polyubiquitinated proteins and catalyze their
unfolding and translocation into the 20S particle [1]. Protea-
some function is also regulated by the association of the 20S
with additional regulatory complexes [2], whose precise phys-
iological importance is still unclear (e.g., PA28ab, the g-inter-
feron-induced complex that functions in antigen presentation;
PA28g; and PA200/Blm10). Also associated with the 26S pro-
teasome are the deubiquitinating enzymes (DUBs) USP14 and
Uch37/UCHL5, which help recycle Ub, but also regulate the*Correspondence: alfred_goldberg@hms.harvard.eduparticle’s (proteolytic and ATPase) activities [3]. The degrada-
tion of many Ub conjugates also requires the p97/VCP/Cdc48
ATPase complex, which functions with cofactors to extract
ubiquitinated proteins from larger structures to facilitate their
degradation by proteasomes [4]. The best-characterized role
of p97 is in ER-associated degradation (ERAD) [5], through
which misfolded proteins in the ER are ubiquitinated and ex-
tracted by p97 in complex with Npl4/NPLOC4, Ufd1/UFD1L,
and p47/NSFL1C [6].
Proteasomes are essential for cell viability but are especially
important in multiple myeloma cells [7]. Consequently, protea-
some inhibitors such as bortezomib (BTZ) or carfilzomib have
become the preferred therapy for this cancer. One challenge in
their use is the occurrence of drug resistance, but the respon-
sible mechanisms are largely unclear [8]. Therefore, informa-
tion on how cells compensate for proteasome inhibition is of
appreciable interest. Upon proteasome inhibition, mammalian
cells show increased expression of multiple 26S subunits,
which elevate proteasome content and promote survival
[9–11]. This response limits the ability of proteasome inhibitors
to kill myeloma cells. Thus, blocking this compensatory
response may enhance the efficacy of this treatment.
Conversely, decreased proteasome function due to the accu-
mulation of aggregation-prone proteins seems to be important
in the pathogenesis of neurodegenerative diseases [12], and
pharmacological induction of proteasomes may enhance the
cells’ degradative capacity and prevent the accumulation of
toxic proteins.
In mammals, upon proteasome inhibition, the transcription
factor Nrf1/NFE2L1 mediates the induction of genes encoding
many 26S subunits [9, 10]. Loss of Nrf1 makes cells more sen-
sitive to killing by proteasome inhibitors. Nrf1, like its homolog
Nrf2/NFE2L2, recognizes antioxidant response elements
(AREs) in the promoters of many proteasome genes [9, 10].
However, Nrf2 induces 26S subunits only during oxidative
stress, but not upon proteasome inhibition. Nrf1 is degraded
by the UPS, with a half-life of onlyw12 min [10]. Upon protea-
some inhibition, ubiquitinated Nrf1 is readily detected, and
several Ub ligases (HRD1, Fbw7/FBXW7, and b-TRCP) have
been implicated in Nrf1 ubiquitination [10, 13, 14]. It is currently
believed that proteasome inhibitors activate Nrf1 by blocking
its rapid degradation [10, 14]. One basic problemwith this sim-
ple mechanism is that it does not explain why Nrf2 does not
play a similar role, given that it is also degraded by the UPS,
with a half-life of w13 min [15]. An unusual characteristic of
Nrf1 is that it is associated with the ER. Therefore, activation
of Nrf1 requires its release from the ER via proteolytic process-
ing by an unidentified protease [10], which presumably is acti-
vated upon proteasome inhibition.
It is also unclear whether proteasome inhibition coordinately
induces the expression of other components of the UPS, such
as PA28, immunoproteasome subunits, proteasome assembly
chaperones (POMP, p27/PSMD9, S5b/PSMD5, and gankyrin/
PSMD10) [16, 17], 26S-associated DUBs (USP14 and Uch37),
and p97 plus its major cofactors. Here, we investigated
whether exposure to proteasome inhibitors causes coordinate
induction of all 26S subunits and these related factors. Our
study has focused on neuroblastoma and myeloma cells,
Figure 1. Proteasome Inhibitors Cause Induction of All 26S Proteasome Subunits, p97, and Its Cofactors in ERAD
(A and B) Treatment of neuroblastoma SH-SY5Y cells with BTZ (10 nM, 16 hr) induced mRNAs for all 26S subunits, measured by RT-PCR (p < 0.05 for all
changes) (A), and increased levels of Rpt5 and 20S subunits, measured by western blot (WB) (B). Biological duplicates were assayed, and levels of Ub con-
jugates were measured to prove proteasome inhibition. Ctrl, control.
(C andD) Treatment of SH-SY5Y cells with BTZ (10 nM, 16 hr) also inducedmRNAs for p97 and its cofactors, Npl4, Ufd1, and p47 (C) and increased content of
p97 protein (*p < 0.05) (D).
Error bars represent SD. See also Figure S1.
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therapy and the apparent decreased proteasome function in
neurodegenerative disease. These two types of cells are also
interesting to study becausemyeloma cells are especially sen-
sitive to killing by proteasome inhibitors, but neurons are rela-
tively insensitive. We also attempted to determine how quickly
these genes are induced after proteasome inhibition, whether
all proteasome inhibitors have similar effects, and how the de-
gree of inhibition of proteolysis influences this response. Our
study uncovered the surprising finding that high concentra-
tions of these agents were less effective than low ones in
inducing this Nrf1-dependent response. In studies to under-
stand this unusual concentration dependence, we found that
some proteasome function is necessary for catalyzing the
proteolytic processing of Nrf1 on the ER, which allows the pro-
cessed Nrf1 (lacking its N-terminal region) to enter the nucleus
and enhance expression of 26S subunits and p97.
Results
Proteasome Inhibition Rapidly Induces 26S Subunits
Independently of the Unfolded Protein Response
In the neuroblastoma line SH-SY5Y, treatment with a low con-
centration (10 nM) of BTZ for 16 hr caused a maximal (2- to
4-fold) increase in mRNAs for all 33 proteasome subunits (Fig-
ure 1A; Figure S1A available online) and about a 50% increase
in their protein levels (Figure 1B). The magnitude of this induc-
tion was similar for both 19S and 20S subunits, including Rpn6
[18] and Rpn11 [19], that were reported to be regulated inde-
pendently, and the loosely associated subunit Ecm29/
KIAA0368 (Figure S1B). At higher concentrations (1 mM), BTZcaused a clear induction of these mRNAs at 4 hr (Figure S1C),
although the magnitude was much smaller than at 16 hr. A
similar induction was detected in another neuroblastoma
line, M17; the myeloma line MM1.S; and HEK293A cells (Fig-
ure S1D), although these lines differed in the degree of induc-
tion. SH-SY5Y cells induced 26S subunits much more strongly
than others. Therefore, we mainly used SH-SY5Y cells in sub-
sequent experiments. Several other proteasome inhibitors,
including MG262 (Z-LLL-boronate) and epoxomicin (Epox),
caused a similar induction of 26S subunits (Figure S1E).
Thus, their induction appears to be a general cellular mecha-
nism that compensates for reduced proteasome function.
The unfolded protein response (UPR) is triggered by the
accumulation of misfolded proteins in the ER and is strongly
induced by proteasome inhibitors [20]. Therefore, we tested
whether the UPR per se induces 26S expression. Unlike BTZ,
the UPR inducers, tunicamycin and thapsigargin, did not stim-
ulate 26S induction (Figures S1E–S1H). Also, low concentra-
tions of BTZ induced 26S subunits without causing the UPR
(i.e., eIF2a phosphorylation; Figure S1F). Thus, proteasome in-
duction is not mediated by the UPR.
Components of the UPS that Are Induced with 26S
Subunits
We next determined whether these inhibitors also stimulated
expression of several proteasome-associated proteins. In
response to g-interferon, cells induce three distinct catalytic
subunits (immunoproteasome subunits), b1i/PSMB9, b2i/
PSMB10, and b5i/PSMB8, which are more efficient in gener-
ating peptides suitable for antigen presentation on major
histocompatibility complex class I molecules [21]. Unlike the
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units decreased by 50%–70% (Figure S1I). PA28a and PA28b
are also induced by g-interferon, and together this complex
can also enhance antigen presentation [22]. BTZ treatment
caused a small decrease in PA28ab mRNA expression. BTZ
did not alter the expression of the nuclear homolog PA28g
(Figure S1I). However, BTZ treatment did induce the other nu-
clear activator, PA200 (Figure S1I).
The assembly of newly synthesized subunits into mature
proteasomes requires assembly chaperones. BTZ treatment
induced the 20S chaperone POMP [17], but not the chaper-
ones involved in assembly of the 19S base, S5b, p27, or Gan-
kyrin [16] (Figure S1J). The 26S-associated DUBs, USP14 and
Uch37, catalyze disassembly of Ub chains on substrates and
can promote protein deubiquitination without degradation
[3], but they also allosterically regulate 20S gate opening and
ATP hydrolysis [23]. Treatment with BTZ or MG132 for 16 hr
induced the mRNA for USP14 2-fold, but surprisingly did not
affect Uch37 expression (Figure S1K). p97 and its cofactors
Npl4, Ufd1, and p47 are essential for the degradation of
many proteins, especially by ERAD. These genes were
induced 2- to 5-fold by BTZ treatment coordinately with 26S
subunits (Figures 1C, 1D, and S1C). However, BTZ did not
induce RAD23A or RAD23B, both of which can shuttle Ub con-
jugates to proteasomes in ERAD (Figure S1L).
Thus, upon proteasome inhibition, mammalian cells induce
all 26S components, USP14, PA200, and the p97 complex,
which together should enhance the cell’s capacity for proteol-
ysis. Furthermore, BTZ treatment increased expression of the
polyubiquitin gene UBB (2- to 3-fold; Figure S1M). Given that
Ub conjugates accumulate upon proteasome inhibition and
free Ub can be depleted [24], its increased production presum-
ably compensates for decreased Ub recycling and enhances
the cell’s capacity for proteolysis.
High Concentrations of Proteasome Inhibitors Inhibit the
Induction of 26S Subunits
All the agents used in this study preferentially inhibit the pro-
teasome’s chymotrypsin-like activity but vary in their affinities
for this site. MG132 is commonly used at much higher concen-
trations than BTZ, Epox, and MG262. Treatment of SH-SY5Y
cells with 10 mM MG132 for 16 hr blocked the chymotrypsin-
like site without causing substantial cell death (Figures S2A–
S2C), but surprisingly did not induce any of the a subunits,
six of the b subunits, or many of the 19S subunits (Rpt4,
Rpt5, Rpn3, Rpn8, Rpn10, and Rpn12) (Figure 2A). In addition,
MG132 caused a smaller induction of Rpt3, Rpn3, Rpn6, and
Rpn14 than did BTZ, though it caused a similar induction of
Rpt2 Rpn1, Rpn2, Rpn5, Rpn7, and Rpn13. Strikingly, when
cells were exposed to both MG132 (10 mM) and BTZ (10 nM)
(Figures S2D and S2E), the inhibitory effect of MG132 was
dominant over the induction of 26S and p97 by low concentra-
tions of BTZ or other inhibitors. Furthermore, in contrast to
10 mM, lower MG132 concentrations (1–2.5 mM) did induce
the expression of 26S subunits (Figure S2F), as reported previ-
ously [9, 10].
Thus, MG132 inhibits proteasome induction only at high
concentrations, at which this tripeptide aldehyde can also
inhibit several cellular serine and cysteine proteases. There-
fore, at such concentrations, MG132’s ability to block induc-
tion of 26S subunits and p97might be due to an effect on these
other proteases (see Figures S3O–S3W) or its causing a
greater inhibition of proteasome function by inhibiting both
the caspase-like and the chymotrypsin-like activities [25]. Totest these possibilities, we investigated the effects of higher
concentrations of the much more specific peptide boronate
proteasome inhibitors, BTZ and MG262 [26], and Epox, an
epoxyketone that specifically inactivates the 20S threonine
proteases [27]. At high concentrations (10 mM), BTZ, MG262,
and Epox all suppressed the induction of 26S subunits and
p97 (Figures 2B and 2C) without causing detectable cytotox-
icity at 16 hr (Figures S2B and S2C), in sharp contrast to the
increased expression of these genes with low concentrations
(10 nM BTZ, 50 nM Epox, 1 mM MG262; Figures 2B, 2C, and
S3L). Similarly, in HEK293A cells, high concentrations of BTZ
inhibited the expression of 26S subunits (Figure 2F). In addi-
tion, the levels of 26S and p97 protein, as well as the amount
of assembled 26S particles, were increased by low, but not
high concentrations of BTZ (Figures 2D and 2E).
At these high concentrations, the inhibitors all blockmultiple
peptidase activities and thusmarkedly reduce cellular proteol-
ysis [25]. Most likely, these high concentrations prevent induc-
tion of 26S subunits by causing a greater inhibition of the
proteasome. Therefore, we compared in HEK293A cells the
effects of increasing BTZ concentrations on 26S expression,
the extent of inhibition of the degradation of long-lived cell
proteins labeled with [3H]-phenylalanine, and the degree of
inhibition of the 26S subunit’s chymotrypsin-like and cas-
pase-like activities in cell lysates (tested with specific fluores-
cent peptide substrates [28]). At 20 nM, BTZ inhibits the
chymotrypsin-like site >50%, but 50 nM is required to inhibit
it by 100% and to inhibit the caspase-like activity and pro-
tein-degradation rate by >50% (Figures 2G and 2H). Intrigu-
ingly, in these cells, maximal induction of 26S subunits b3,
Rpt3, and Rpt5 occurred with 20 nM BTZ, but at 50 nM and
higher, BTZ progressively inhibited the expression of these
genes (Figure 2F). Therefore, greater inhibition of protein
degradation (e.g., with high concentrations that block the
chymotrypsin-like activity completely and also inhibit the cas-
pase-like activity), suppressed the expression of 26S subunits
and p97.
The Induction of 26S Subunits Requires Cleavage of the
ER-Bound Transcription Factor Nrf1 and Some
Proteasome Function
We confirmed the prior finding [9] that Nrf1 is the critical factor
inducing 26S subunits after BTZ treatment by showing that
stable Nrf1 knockdown in SH-SY5Y cells suppressed the in-
duction of many 26S subunits’ mRNAs and decreased their
basal mRNA levels (Figures S3A and S3B). Thus, Nrf1 appears
to be important in determining proteasome content under
normal conditions. By contrast, knockdown or overexpression
of Nrf2 did not affect 26S induction upon BTZ treatment (Fig-
ures S3C–S3F). Nrf1 is normally associated with the ER
through its N terminus, and deletion of the 30 N-terminal
residues allows its translocation into the nucleus and the
stimulation of gene expression [14, 29, 30]. Therefore, it was
hypothesized that a proteolytic cleavage of Nrf1 near its N ter-
minus releases it from the ER [10], and during preparation of
this manuscript, Nrf1 was reported to be cleaved before
Leu104 [31]. However, no specific protease has been impli-
cated in this step. As discussed above, the most likely expla-
nation for the ability of high concentrations of proteasome
inhibitors to suppress induction is that the 26S itself processes
Nrf1 and high concentrations of inhibitors block its capacity for
limited proteolysis.
We therefore tested whether Nrf1 was proteolytically pro-
cessed upon exposure to low, but not high concentrations of
Figure 2. High Concentrations of Proteasome Inhibitors Block the Induction of 26S Subunits
(A) Unlike the treatment of SH-SY5Y cells with low concentrations of BTZ (10 nM), 10 mMMG132 for 16 hr did not induce themRNA for 20S subunits andmany
of the 19S subunits. (*, genes whose mRNA levels are lower [p < 0.05] in MG132-treated than in BTZ-treated cells.)
(legend continued on next page)
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Figure 3. High Concentrations of Proteasome In-
hibitors Block the Proteolytic Processing of Nrf1
(A) Treatment of SH-SY5Y cells with high concen-
trations (10 mM) of MG132, BTZ, or MG262 for
16 hr, alone or with 10 nM BTZ, suppressed the
processing of Nrf1. FL, full-length Nrf1; P, pro-
cessed Nrf1.
(B) Epox treatment for 16 hr at 10 mM, but not
50 nM, suppressed Nrf1 processing.
(C) BTZ or Epox treatment (SH-SY5Y cells) for
16 hr at concentrations higher than 0.5 mM de-
creases the processing Nrf1.
(D) Treatment of HEK293A cells with BTZ for 16 hr
at >20 nM causes the accumulation of FL Nrf1
and >1 mM decreases the level of P Nrf1.
See also Figure S3.
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1577proteasome inhibitors. Using an antibody that recognizes the
C terminus of Nrf1 (C-19), we could detect the full-length (FL)
Nrf1 (w85 kDa) plus a smaller form (w75 kDa) in cells treated
with 10 nMBTZ (Figures S3B, S3G, and S3H). These two bands
also reacted with another Nrf1 antibody (H-285, which recog-
nizes residues 191–475), and levels of both were diminished
by the Nrf1 small hairpin RNA (shRNA) (Figure S3B). The
appearance of this smaller form upon BTZ treatment strongly
suggests that it is a processed (P) form of Nrf1. Inhibition of
protein synthesis by cycloheximide (CHX) after 4 hr of BTZ
(20 nM) treatment caused a rapid decline in the levels of both
FL and P forms (Figure S3J). Thus, both forms of Nrf1 have
short half-lives even in the presence of 10 nMBTZ. Upon treat-
ment with 20 nM BTZ, the P form gradually accumulated, and
its level was much higher at 8–12 hr than at 4 hr (Figure S3J).
However, ATP depletion during proteasome-inhibitor treat-
ment completely abolished Nrf1 processing (Figure S3K),
implying that generation of the P form involves an ATP-depen-
dent process, such as the UPS.
We next tested whether Nrf1 processing is blocked by high
concentrations of proteasome inhibitors. Nrf1 was processed
in both SH-SY5Y cells (Figure 3A) and MM1.S cells (Figure S3I)
treated with 10 nMBTZ, which caused 26S subunits’ induction
(Figure S1D), but not with 10 mM MG132, which failed to stim-
ulate their expression. Similarly, high concentrations (10 mM) of
BTZ, Epox, or MG262 also suppressed Nrf1 processing (Fig-
ures 3A and 3B), just as they prevent proteasome induction,
whereas at low concentrations that permitted induction, these
inhibitors caused Nrf1 processing (Figures 3A, 3B, and S3L–
S3N). Furthermore, treatment with 10 mM MG132 or MG262
together with 10 nM BTZ suppressed the processing of Nrf1
(Figure 3A), just as these combinations repressed 26S expres-
sion (Figure 2B). We confirmed these observations using both
C-19 and H-285 antibodies to monitor Nrf1 processing.
Because the H-285 antibody recognizes the processed Nrf1
muchmore strongly thanC-19, H-285was used inmost subse-
quent experiments.(B) High concentrations (10 mM) of BTZ or MG262, alone or in combination wit
(C) Treatment with Epox at 10 mM, but not 50 nM, suppressed the induction of
(D and E) SH-SY5Y cells were treated with BTZ for 16 hr. (D) The level of 26S sub
or DC) 26S proteasomes were separated by native PAGE, and their activity and
a123567 antibody.
(F–H) BTZ inhibits 26S subunit expression in HEK293A cells at 50 nMor higher. (G
substrates. (H) The protein degradation rate was measured by assaying hydrol
Rpt3, and Rpt5 mRNAs were measured.
Arrows indicate 50 nM, above which BTZ blocks protein degradation and 26STo determine the minimal concentrations at which protea-
some inhibitors begin to block Nrf1 processing, we compared
the effects of increasing concentrations of BTZ, Epox, and
MG132 in SH-SY5Y cells. MG132 was able to enhance Nrf1
processing (Figure S3N) and to induce subunit expression
(Figure S2F) at 1 or 2.5 mM, but at higher concentrations (5 or
10 mM), both Nrf1 processing and proteasome gene expres-
sion were suppressed. When the concentrations of the more
potent and specific inhibitors BTZ and Epoxwere raised above
0.5 mM, the level of the P form started to decrease in SH-SY5Y
(Figure 3C) and HEK293A cells (Figure 3D). A more sensitive
indicator of the incomplete processing of Nrf1 was the accu-
mulation of FL Nrf1. In SH-SY5Y cells, FL Nrf1 is present at
very low concentrations (probably due to its very rapid degra-
dation) and was barely detectable by the H-285 antibody.
However, in HEK293A cells, BTZ (R50 nM) was able to cause
FL Nrf1 accumulation (Figure 3D), and thus, at these concen-
trations, BTZ must already inhibit Nrf1 processing. Remark-
ably, 50 nM is exactly the concentration at which BTZ
suppressed the expression of 26S subunits (Figure 2F). Also,
50 nM is the concentration at which BTZ causes complete in-
hibition of the chymotrypsin-like activity and also inhibits the
caspase-like activity and cellular protein degradation >50%
(Figures 2G and 2H). These extensive correlations make it
very likely that the proteasome is responsible for Nrf1 process-
ing to the active form. Therefore, only when proteasomes are
partially compromised by low inhibitor concentrations that
only partially block the chymotrypsin-like site will there be suf-
ficient 26S function for limited proteolysis of Nrf1. However,
when multiple active sites are inhibited and protein degrada-
tion is reduced >50%, Nrf1 processing cannot take place.
Although the proteasome is the only known enzyme in
mammalian cells sensitive to epoxyketones [27], we carried
out extensive tests of the unlikely possibility that Nrf1 is pro-
cessed by an additional protease that is inhibited by peptide
aldehydes and/or peptide boronates or an ER-associated in-
tramembrane protease. By inhibiting these proteases withh 10 nM BTZ, suppressed the induction of a3, b3, Rpt3, and p97.
20S subunit mRNAs. *p < 0.05.
units and p97 were determined byWB. (E) Next, singly or doubly capped (SC
amounts were determined by Suc-LLVY-AMC overlay assay or WB with the
) Peptidase activitiesweremeasured in cell lysates with fluorogenic peptide
ysis of radiolabeled long-lived cell proteins to acid-soluble products. (F) b3,
induction. Error bar represents SD. See also Figure S2.
Figure 4. Low, but Not High Concentrations of
Proteasome Inhibitors Cause the Processing of
Nrf1 near Its N Terminus
(A) Nrf1 taggedwith HA at its N terminus (HA-Nrf1)
or C terminus (Nrf1-HA) was expressed in
HEK293A cells. Nrf1-HA and HA-Nrf1 exist in
both a glycosylated form (G, which is hardly
detectable for the endogenous Nrf1 under most
conditions) and a deglycosylated form (FL,
because both full-length forms retain the HA
epitope regardless of whether Nrf1 was tagged
at its N or C termini). After treatment with Epox
(20 nM, 16 hr), theHA tag still remainedon thepro-
cessed form of Nrf1-HA, but not on the product of
HA-Nrf1. (Biological duplicates were assayed.)
(B) The processing of Nrf1-HA is most efficient with 20 nM Epox treatment that retains 18.3% chymotrypsin-like activity, whereas 20 nMBTZ treatment (that
retains only 5.1% chymotrypsin-like activity and 14.0% caspase-like activity) partially suppressed Nrf1-HA processing. Higher concentrations of BTZ or
Epox blocked Nrf1-HA processing.
See also Figure S4.
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strong data (Figures S3O–S3W) indicating that the various
potential candidates, including MG132-sensitive proteases
(calpain and lysosomal cathepsins) or ER-associated intra-
membrane proteases (g-secretase, signal peptidase, and
ER-associated rhomboid family intramembrane proteases)
do not play a role in processing Nrf1 upon proteasome inhibi-
tion and expression of 26S subunits (See the legend of Figures
S3O–S3W for detailed discussion). Together, these various
negative observations and the extensive correlations shown
above make it very likely that Nrf1 processing is mediated by
the proteasome itself.
Proteolytic Removal of Nrf1’s N Terminus Is Essential for
Nuclear Entry
Nrf1 contains several ER transmembrane domains, but the
topology of FL Nrf1 has not been resolved. However, the N-ter-
minal transmembrane domain (residues 2–30) is required for
its ER association, and deletion of this region allows nuclear
translocation [29]. To test whether Nrf1 processing involves
proteolytic removal of this N-terminal region, we expressed
FL Nrf1 tagged with hemagglutinin (HA) at its N or C terminus.
FL Nrf1 initially exists as a glycosylated form (G) [10, 30]. After
Epox treatment, the G species was first converted to the FL
form, whose molecular weight decreased due to deglycosyla-
tion (Figure 4A), as reported recently [10]. The identity of the G
and FL species was clear because both retained the HA tag,
whether it was on the N or C terminus (Figure 4A), and the FL
sequence of the G form was confirmed by liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) (Figure S4).
After deglycosylation, Nrf1 was proteolytically processed, as
shown by LC-MS/MS analysis of the shorter form (Figure S4).
When Nrf1 was tagged at its N terminus (HA-Nrf1), the HA tag
was lost during Nrf1 processing, but not when it was tagged on
its C terminus (Nrf1-HA). The HA antibody therefore no longer
reacted with processed HA-Nrf1 (Figure 4A) even though Epox
at low concentrations still induced processing of HA-Nrf1,
which still reacted with the Nrf1 antibody. As expected, the
processed Nrf1-HA was larger than the processed HA-Nrf1,
which no longer contained the HA tag. However, we could
not detect the N-terminal HA tag after it was cleaved off
HA-Nrf1. Like the processing of endogenous Nrf1, Nrf1-HA
processing was very sensitive to proteasome inhibition. An
80% inhibition of the chymotrypsin-like activity by 20 nM
Epox promoted Nrf1 processing, but a greater inhibition of
the proteasome with 100 nM Epox or with 20 nM BTZ, whichinhibits the chymotrypsin-like site completely as well as the
caspase-like site, resulted in a decline in the P form and an
accumulation of the FL form (Figure 4B).
To testwhether the lossof theN terminusactually allowsNrf1
entry into the nucleus [14, 29], we treated HEK293A cells over-
expressing Nrf1-HA with proteasome inhibitors and localized
Nrf1-HAwithanHAantibody.Nrf1-HAwas initiallycytoplasmic,
as expected from its reported ER association, but entered the
nucleus after treatment with BTZ or Epox (Figure 5B). Although
the H-285 antibody detected this nuclear translocation of
HA-Nrf1 (Figure 5C), the HA antibody could not detect any
HA-Nrf1 in the nucleus (Figures 5B and 5C). Thus, Nrf1 could
not enter the nucleus unless its N terminuswas removed. How-
ever, as expected, high inhibitor concentrations (10mMMG132,
Figure 5A; or 500 nM Epox, Figure 5C) blocked Nrf1 accumula-
tion in the nucleus. Thus, someproteasome activity is essential
for Nrf1 release from the ER and nuclear entry.
Nrf1 Processing Requires Ubiquitination, but Is Not
Activated by Heat Shock
Nrf1 is normally polyubiquitinated and rapidly degraded by
proteasomes [10, 13, 14]. It was therefore assumed that pro-
teasome inhibitors cause gene induction simply by blocking
Nrf1 degradation [10]. However, this model is inconsistent
with our finding that high concentrations of these inhibitors
prevent Nrf1 degradation but do not induce 26S subunit
expression. Instead, Nrf1 activation and induction of 26S
subunits and p97 require some proteasome activity to pro-
cess Nrf1 and allow nuclear entry. To determine whether
the processing of Nrf1 by the 26S also requires the ubiquiti-
nation of Nrf1, we treated cells for 16 hr with BTZ
(10/100 nM) and the specific inhibitor of ubiquitination,
ML00603997 [32]. This treatment almost completely depleted
various cell lines of ubiquitinated proteins within 1 hr (Figures
S5A and S5C) and was not toxic to the cells during 24 hr.
Blocking ubiquitination dramatically suppressed BTZ-
induced expression of 26S subunits and p97 below their
basal mRNA level (Figures 6A and S5B) and also completely
suppressed the processing of endogenous Nrf1 induced by
BTZ (Figures 6B, S5A, and S5C). Similarly, inhibiting ubiquiti-
nation prevented the processing of overexpressed Nrf1-HA in
HEK293A cells and caused it to accumulate in its FL form
(Figure 6C). Furthermore, this inhibitor alone caused the
accumulation of FL Nrf1. Thus, ubiquitination is required for
BTZ-induced Nrf1 processing and the induction of 26S sub-
units and p97.
Figure 5. Nrf1 Nuclear Translocation with Low,
but Not High Concentrations of Proteasome In-
hibitors Requires Its N-Terminal Processing
(A) HEK293A cells overexpressing Nrf1-HA were
treated with BTZ (10 nM), Epox (50 nM), or
MG132 (10 mM) for 16 hr, and Nrf1-HA localization
was detected by HA immunostaining. Nuclear
translocation of Nrf1-HA occurred after treatment
with BTZ and Epox, but not MG132.
(B) After HEK293A cells overexpressing Nrf1-HA
or HA-Nrf1 were treated with BTZ (10 nM) or
Epox (20 nM) for 16 hr, HA immunostaining de-
tected Nrf1-HA, but not HA-Nrf1, in the nuclei of
the BTZ- or Epox-treated cells.
(C) HEK293A cells overexpressing Nrf1-HA or
HA-Nrf1 were treated with Epox (20 or 500 nM)
for 16 hr. Nrf1 antibody, but not the HA antibody,
could detect nuclear HA-Nrf1 upon 20 nM Epox
treatment. Like 10 mM MG132, 500 nM Epox did
not induce Nrf1 nuclear translocation.
All scale bars represent 50 mm.
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duces Nrf1 processing and proteasome production could be
that reduced proteasome function activates Nrf1-mediated
gene induction by causing an accumulation of misfolded or
ubiquitinated proteins. However, merely increasing protein
misfolding and the level of Ub conjugates in the cytosol by
treating SH-SY5Y cells with arsenite or heat shock not onlyfailed to promote Nrf1 processing, but
surprisingly, even blocked this process
and the induction of 26S subunits and
p97 by BTZ (Figures S5D–S5G). There-
fore, Nrf1 processing and production
of new proteasomes is not signaled by
an accumulation of misfolded or ubiqui-
tinated proteins, which actually reduces
these processes. Alternatively, Nrf1may
need to be ubiquitinated in order to be
processed by the proteasome. We
tested this possibility using RA190 [33],
an inhibitor of Rpn13, one of two protea-
some subunits that bind Ub chains.
RA190 binds covalently to Rpn13’s Ub-
binding domain and thus seems to
block the association of conjugates
with the 26S [33]. Rpn13 inhibition
blocked the accumulation of processed
Nrf1 in HEK293A and SH-SY5Y cells and
reduced the induction of 26S expres-
sion by 20 nM of BTZ (Figures S5H–
S5L). Therefore, Nrf1 processing
requires recognition of ubiquitinated
species by the 26S. Most likely, E1 inhi-
bition stops Nrf1 processing by block-
ing its ubiquitination and binding to the
26S and not by reducing the cell’s con-
tent of Ub conjugates.
Nrf1 Processing Requires p97
Function for Its Deglycosylation
This ubiquitination and proteasome-
mediated limited proteolysis of Nrf1 re-
sembles the processing of three othertranscription factors, NF-kB [34], Gli [35], and Spt23 [36]. The
processing of Spt23, which is also ER associated, requires
p97 to extract the processed Spt23 from the ER [36]. To test
whether p97 is also essential for Nrf1 processing, we ex-
pressed a dominant-negative mouse p97K524A (DN-p97)
that cannot bind ATP [37] or treated cells with the p97 inhibitor
NMS859, which also blocks ATP binding [38]. As expected,
Figure 6. Nrf1 Processing and the Expression
of 26S Subunits and p97 Require Nrf1 Ubiquiti-
nation
(A and B) SH-SY5Y cells were treated with the E1
inhibitorML00603997 (E1-In, 0.5 mM) for 1 hr, then
treated with different concentrations of BTZ
together with 0.5 mM ML00603997 for 16 hr. E1-
In suppressed both (A) expression of mRNA for
p97 and the 26S subunit b3 and (B) the process-
ing of Nrf1. (Biological duplicates were assayed.)
(C) HEK293A cells expressing Nrf1-HA were
treated with E1-In as in (A) and (B) and different
concentrations of proteasome inhibitors. E1-In
caused the accumulation of full-length Nrf1-HA by
itself or in the presence of proteasome inhibitors.
Error bar represents SD. See also Figure S5.
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gates (Figure S6). Upon BTZ treatment (50 nM, 4 hr), DN-p97
also caused an accumulation of the glycosylated form of
Nrf1 but decreased the levels of both the FL and the P forms
of Nrf1 (Figures 7A and S6B). The same effects were observed
in HEK293A cells and SH-SY5Y cells treatedwith the p97 inhib-
itor (Figures S6E and S6F) at concentrations that do not cause
cell death (Figure S6D). The DN-p97 also blocked the forma-
tion of both the FL and P forms of ectopically expressed
Nrf1-HA (Figure 7B). Therefore, p97 function is necessary for
the production of the deglycosylated FL form. As these
findings predict, the DN-p97 also prevented Nrf1 entry into
the nucleus upon treatment with 20 nM BTZ and reduced the
expression of 26S subunits (Figures S6C and S6H). Similarly,
the p97 inhibitor also abolished induction of 26S subunits
and p97 in HEK293A and SH-SY5Y cells (Figures S6G and S6I).
Because FLNrf1 accumulated upon E1 inhibition, whereasG
Nrf1 accumulated when p97 was inhibited, Nrf1 must be ubiq-
uitinated after its deglycosylation. To test this conclusion, we
treated HEK293A cells coexpressing Nrf1-HA and DN-p97
with the E1 inhibitor. Although blocking ubiquitination alone
caused a buildup of Nrf1 in the FL form, inhibition of both E1
and p97 led to an accumulation of Nrf1 in the G form (Fig-
ure 7B). Therefore, Nrf1 must be ubiquitinated again after its
deglycosylation.
Discussion
The increased production of new proteasomes after treatment
with proteasome inhibitors is an important compensatory
response that promotes cell survival and is likely to reduce
therapeutic efficacy. As shown here, this response involves
coordinate induction of all the standard proteasome subunits
via Nrf1 as well as several other key UPS components. The
20S assembly chaperone POMP, but not chaperones involved
in 19S base assembly (S5b, p27, and Gankyrin) were induced,
presumably because POMP is destroyed during 20S assem-
bly. The simultaneous induction of PA200 is interesting given
that PA200 can promote Ub-independent proteasomal degra-
dation of certain proteins [39]. On the other hand, the lack of
induction of immunoproteasome subunits and PA28ab corre-
lates with their functioning predominantly in antigen presenta-
tion and regulation by g-interferon, rather than in protein
degradation. In fact, expression of immunoproteasomes was
suppressed by BTZ, as was also noted previously [10, 11],
and none of these genes contains an ARE sequence in its
promoters. Clearly, their production is regulated differently
from standard proteasomes. Proteasome inhibition inducedUsp14, but surprisingly not the other 26S-associated DUB,
Uch37, even though it, like Usp14, activates gate opening
andATP hydrolysis upon binding of Ub conjugates [23]. Never-
theless, the finding that Uch37 expression is not coordinately
regulated suggests that these two 26S-associated DUBs serve
distinct roles. Lastly, our finding that p97 and its cofactors
(Ufd1, Npl4, and p47) were strongly induced together with pro-
teasome subunits is consistent with their important general
role in the UPS.
This simultaneous induction of UBB, PA200, USP14, and
p97 plus its ERAD cofactors suggests strongly that these
proteins are all important in enhancing the cell’s proteolytic ca-
pacity. However, simultaneous induction does not prove that
the mechanisms are the same. In fact, high concentrations of
proteasome inhibitors inhibited the induction of p97 together
with 26S subunits, but not the induction of USP14, Ecm29,
and UBB, which thus must not require Nrf1. Nrf1-dependent
induction of all proteasome subunits and p97 differs sharply
from the selective induction of Rpn6 by FOXO4 [40]. This
response to proteasome inhibition also clearly differs from
the heat-shock response and the UPR [20, 41], both of which
are caused by the buildup of misfolded proteins and therefore
can also be induced by proteasome inhibitors. Neither theUPR
nor heat shock leads to Nrf1 processing or induction of 26S
subunits. In fact, surprisingly, heat shock suppresses this
response to proteasome inhibition (Figures S5D–S5G). Among
four cell lines tested, the induction of 26S subunits was stron-
gest in SH-SY5Y cells, but this property is not general for all
neuronal cells because another neuroblastoma line, M17,
induced the expression of 26S subunits much more weakly
(Figure S1D) despite being more resistant to killing by BTZ
than SH-SY5Y cells (data not shown). Therefore, although
both neuroblastoma lines were much more resistant to killing
by BTZ than the myeloma line MM1.S, this greater resistance
cannot be attributed to a greater ability to induce the expres-
sion of 26S subunits.
Because Nrf1 is a short-lived protein, it was believed that
upon proteasome inhibition, Nrf1 is activated simply because
its degradation is prevented [10, 13, 14]. Such a mechanism is
unable to explain our finding that 26S subunits and p97 are
induced upon treatment with low, but not high concentrations
of proteasome inhibitors. In fact, this mechanism would pre-
dict the exact opposite result, i.e., greater Nrf1 activation at
higher concentrations. Our results instead support the type
of mechanism illustrated in Figure 7C, in which 26S protea-
somes catalyze not only the complete degradation of Nrf1
[14], but also limited proteolysis to release Nrf1’s active region
from its N-terminal transmembrane domain. BecauseNrf1 also
Figure 7. Nrf1 Processing and the Expression of
26S Subunits and p97 Require Nrf1 Deglycosyla-
tion and p97 Activity
(A) To test whether p97 function is essential for
Nrf1 processing, we incubated HEK293A cells
overexpressing GFP-p97, GFP-DN-p97, or GFP
(control) with or without 50 nM BTZ for 4 hr.
GFP-DN-p97 (but not GFP-p97) reduced the
levels of full-length and processed Nrf1 but
caused the accumulation of a 100 kDa glycosy-
lated form of Nrf1.
(B) DN-p97 and Nrf1-HA were coexpressed in
HEK293A cells. DN-p97 caused the sequestra-
tion of Nrf1-HA in its glycosylated form and
blocked the formation of full-length and pro-
cessed Nrf1 upon treatment (12 hr) with BTZ
(20 nM) or E1-In (0.5 mM).
(C) Model: Upon partial inhibition of proteasomes
with low concentrations of inhibitors, cells induce
26S subunits and p97 via Nrf1. Although Nrf1 is
normally degraded completely, partial inhibition
of proteasomes by low concentrations of inhibi-
tors favors limited degradation of the N-terminal
part of Nrf1. Consequently, the processed
C-terminal portion of Nrf1 is released from the ER and enters the nucleus to transcribe 26S subunits and p97. Complete inhibition of proteasomes by
high concentrations of inhibitors blocksNrf1 processing and transcription. BothNrf1 degradation and its proteolytic processing require first deglycosylation
and extraction of Nrf1 from the ER via p97 activity, and second, ubiquitination of Nrf1.
See also Figure S6.
Regulation of Nrf1 Processing and 26S Production
1581regulates basal expression of 26S subunits (Figure S3A), both
Nrf1 degradation and processing probably also occur under
normal conditions, but with reduced proteasome function,
processing is favored.
A variety of observations support this model, especially our
demonstration that some proteasome function is essential for
Nrf1 processing and its translocation into the nucleus. Specif-
ically, BTZ most efficiently induced Nrf1 processing and 26S
subunit expression at low concentrations that only partially
block the chymotrypsin-like site and cause only a minor
(<40%) decrease in proteolysis (Figures 2F–2H and 3D). By
contrast, higher concentrations that completely block this
site and also cause a large (>50%) inhibition of the caspase-
like site and protein breakdown inhibit Nrf1 processing,
nuclear entry, and 26S induction. Thus, although active protea-
somes tend to degrade Nrf1 completely, partially inhibited 26S
subunits no longer digest ubiquitinated Nrf1 processively and
tend to release partially digested Nrf1, which activates tran-
scription. When 26S function is blocked to a greater extent,
the inactive Nrf1 precursor is stabilized, and the expression
of 26S subunits and p97 is blocked.
The precise mode of processing of ubiquitinated Nrf1 by the
partially inhibited 26S subunit remains uncertain. Although the
N-terminal HA tag on Nrf1 and the transmembrane segment
were not detected after they were cleaved fromHA-Nrf1, these
observations do not distinguish whether Nrf1 is partially
digested from its N terminus or, as seems more likely, pro-
teasomal cleavage is initiated from an internal loop near the
transmembrane segment, followed by degradation of the
N-terminal part, perhaps by an ER-associated peptidase
(e.g., signal peptidases). Whereas 26S generally degrade pro-
teins in a processive manner, incomplete degradation begin-
ning from one end or from an internal loop and release of large
fragments are often observed with isolated proteasomes [42].
Perhaps simply the slowing of proteasomal function, as occurs
with low concentrations of inhibitors, enhances the probability
of release of Nrf1’s C-terminal part. The lack of processivity
leading to its release may depend on the tightness of foldingof its different domains, the direction of translocation into
20S [42], the site(s) of ubiquitination, and the length or number
of Ub chains on the substrate. Three E3s have been reported to
act on Nrf1: HRD1, an ER-associated E3; b-TRCP, a nuclear E3
that probably catalyzes degradation of the mature Nrf1; and
Fbw7, which acts on multiple growth-related proteins [13,
14]. Exactly how these E3s (or others) influence the complete
degradation or processing of Nrf1 is an important issue for
future research.
This mechanism (Figure 7C) for Nrf1 maturation resembles
the 26S-catalyzed processing of inactive precursors by pro-
teasomes and p97 to three other transcription factors: NF-kB
[34], Gli [35], and the ER-bound Spt23 in yeast [36]. These other
examples, like Nrf1 processing, require precursor ubiquitina-
tion and ATP. In these respects, Nrf1 resembles a typical
ERAD substrate. Not surprisingly, p97 is important for Nrf1
degradation by fully active proteasomes [10], aswell as its pro-
cessing by partially inhibited 26S. Nrf1 may translocate across
the ER membrane several times [29]. This complex topology
should block the release of Nrf1 from the ER. Given that p97
activity allows removal of these glycosyl chains (Figures 7A
and S6B), the p97 complex probably extracts most of Nrf1’s
C-terminal part from the ER, so that the subsequent N-terminal
proteolytic processing can release Nrf1. After the present
studies were completed, Deshaies and colleagues reported
studies of Nrf1’s ER topology based on susceptibility to prote-
ase K [31], and they also concluded that Nrf1’s C-terminal part
is initially localized in the ER lumen and was relocated into the
cytosol by p97. We further demonstrated that after Nrf1 is
deglycosylated and its C-terminal region relocated to the
cytosol by p97, Nrf1 needs to be ubiquitinated again in order
to be processed. Thus, p97 functions differently here than in
Spt23 processing, wherein p97 seems to extract Spt23 from
the ER after it has already been processed by the proteasome
[36]. Because p97 is required for Nrf1 processing, p97 inhibi-
tion, like high concentrations of proteasome inhibitors,
suppressed rather than activated the transcription of 26S
genes. Because the p97 inhibitors have potential as
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elicit the compensatory production of more 26S.
The finding that partial proteasome inhibition triggers the
induction of new 26S has clear implications for multiple
myeloma therapy. Because this compensatory response pro-
motes cancer survival [9–11] and increases the chances of
drug resistance, the optimal treatment regimen should be
one that inhibits multiple active sites and achieves more com-
plete inhibition of proteasomes for longer periods. For the opti-
mization of drug administration, monitoring Nrf1 processing
may be a useful biomarker for evaluating the efficacy of
proteasome inhibition and rates of new particle production.
Further understanding of the mechanisms for Nrf1 processing
may also indicate ways to block new proteasome production
for improvement of the treatment of cancer, or conversely,
ways to enhance Nrf1 processing to promote clearance ofmis-
folded proteins in neurodegenerative diseases.
Experimental Procedures
Detailed experimental procedures are presented in the Supplemental
Information.
Gene Overexpression or Knockdown
Lipofectamine 2000 (Life Technologies) was used to transfect plasmids into
HEK293A cells. Stable knockdowns in SH-SY5Y cells were performed by
infectionwith lentiviral particles expressing shRNA and puromycin-resistant
marker.
Immunostaining
Transfected cells were seeded on coverslips in 6-well plates. Treated cells
were fixed with 220C methanol. Images were taken at a Nikon Ti inverted
fluorescence microscope.
Real-Time RT-PCR
mRNAwas extracted via TRIzol Reagent (Life Technologies), and cDNAwas
synthesized usingMultiScribe Reverse Transcriptase (Applied Biosystems).
Real-time RT-PCR was performed using ABsolute Blue qPCR ROX Mix
(Thermo Scientific) on a Bio-Rad C1000 thermal cycler.
Assay of Proteasome Function and Protein Degradation
Proteasomal peptidase activities were measured as described previously
[28]. Native gels and overlay assay with Suc-LLVY-AMC were conducted
as described [43]. The degradation rate of long-lived cell proteins was
measured after labeling with L-Phe-[3,4,5-3H] (American Radiolabeled
Chemicals) as described [44].
Supplemental Information
Supplemental Information includes six figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cub.2014.06.004.
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